MedTrace Logo

The Effects of Dapagliflozin in Normal Clinical Practice in T2D

NCT05418946 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2022-06-14

No results posted yet for this study

Summary

The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with Dapagliflozin in subjects with type 2 diabetes in normal clinical practice.

The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with Dapagliflozin.

Conditions

Interventions

DRUG

Dapagliflozin 10mg

Treatment of T2D and cardio-renal prevention

Sponsors & Collaborators

  • University of Milan

    lead OTHER

Principal Investigators

  • Paolo Fiorina, MD, PhD · University of Milan, ASST-FBF-Sacco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418946 on ClinicalTrials.gov